Adlai Nortye’s Buparlisib (AN2025) Set to Become a Potential Treatment for Anti-PD-1 Non-responding Tumor in HNSCC
NORTH BRUNSWICK, N.J., March 15, 2019 /PRNewswire/ — Adlai Nortye Ltd. (“Adlai Nortye”), a global clinical-stage biopharmaceutical company today released the animal model data of Buparlisib (AN2025) at the 7th…